David Haber
General Partner at Andreessen Horowitz
New York, New York
Overview
Work Experience
General Partner
2021 - Current
Andreessen Horowitz is a stage-agnostic venture capital firm with assets under management across multiple funds.
VP, Firmwide Strategy & Corporate Development (Executive Office)
2019 - 2020
Working with our Chief Strategy Officer on Partnerships, New Ventures and M&A Working with our Co-CIOs and CTO on Firmwide Digital and Technology Strategy (with a focus on externalizing our infrastructure as a developer platform for our clients to build upon) Sourced strategic investments in Carta (Series D/E) & Ualá (Series B)
VP, Strategy & Corporate Development (Digital Finance)
2017 - 2019
Bond Street joined forces with Marcus to grow our Digital Finance business.
Goldman Sachs is a multinational financial services firm providing securities, investment banking, and management services.
Founder, CEO
2013 - 2017
We're building a better future where access to financing for small business owners is simple, transparent and fair. Bond Street joined forces with Goldman Sachs in October 2017 to grow the firm's new Digital Finance business. www.bondstreet.com
Bond Street is a startup focused on transforming small business lending through technology, data, and design.
Raised $411,500,000.00 from Jefferies.
Associate
2011 - 2013
Spark Capital is an early-stage venture capital firm with a focus on social, mobile, ecommerce, marketplace and infrastructure investments. Investments include: Twitter, Tumblr, Plaid, Oculus, Wayfair, Warby Parker, Admeld, Mark43, Orchard, 1stDibs, among others.
Spark Capital is a venture capital firm that invests in the consumer, commerce, FinTech, software, frontier, and media sectors.
Founding Associate
2008 - 2011
Start-up asset management firm lead by Rory Riggs, a veteran private equity investor and biotech entrepreneur.
Data and fintech for company classification, index construction, investment research, portfolio analysis, ESG and SDG measurement
Associate
2008 - 2011
New Ventures is a $150M venture capital fund with investments in biotechnology and health care. (Portfolio includes: Royalty Pharma, Fibrogen, Cibus, GeneNews, DestinationRx, COH, etc.)